Medicine and Dentistry
Primary Central Nervous System Lymphoma
100%
Rituximab
66%
Arm
48%
Autologous Stem Cell Transplantation
48%
Progression Free Survival
46%
Overall Survival
45%
Methotrexate
45%
Quality of Life
38%
B-Cell Chronic Lymphocytic Leukemia
36%
Mantle Cell Lymphoma
36%
Whole Brain Radiotherapy
36%
Drug Megadose
35%
Elderly Patient
31%
Carmustine
28%
Combination Chemotherapy
28%
Thiotepa
27%
Dexamethasone
25%
Non-Hodgkin Lymphoma
24%
Magnetic Resonance Imaging
22%
Allogeneic Stem Cell Transplantation
21%
Diseases
21%
Hematology
20%
Teniposide
20%
Prednisolone
20%
Diffuse Large B-Cell Lymphoma
18%
Fludarabine
18%
Invasive Aspergillosis
18%
Relative Survival
18%
Ixazomib
18%
Waldenström's Macroglobulinemia
18%
Conditioning
18%
Randomized Controlled Trial
18%
Autologous Hematopoietic Stem Cell Transplantation
18%
Ibrutinib
18%
Intravenous Drug Administration
18%
Tumor Microenvironment
18%
Aspergillus
18%
Busulfan
18%
Survival Prediction
18%
Immunocompetent Cell
18%
CAR T-cell therapy
18%
Large-Cell Lymphoma
18%
Chimeric Antigen Receptor T-Cell
18%
Trisomy 8
18%
Acute Myeloid Leukemia
18%
Eosinophilia
18%
Dysplasia
18%
Polymerase Chain Reaction
18%
Pyrrole
18%
Infection
18%
Pharmacology, Toxicology and Pharmaceutical Science
Rituximab
86%
Chronic Lymphatic Leukemia
72%
Progression Free Survival
60%
Overall Survival
46%
Chemotherapy
44%
Nonhodgkin Lymphoma
43%
Primary Central Nervous System Lymphoma
36%
Diffuse Large B Cell Lymphoma
36%
Methotrexate
30%
Infection
21%
Diseases
21%
Mantle Cell Lymphoma
18%
Dasatinib
18%
Chimeric Antigen Receptor
18%
Granulocyte Colony Stimulating Factor
18%
Malignant Neoplasm
18%
Peripheral T Cell Lymphoma
18%
Standardized Incidence Ratio
18%
Large Cell Lymphoma
18%
Yttrium 90
18%
Ibritumomab Tiuxetan
18%
Second Cancer
18%
Ixazomib
18%
Fludarabine
18%
Dexamethasone
18%
Burkitt's Lymphoma
18%
Aspergillus
18%
Invasive Aspergillosis
18%
Alemtuzumab
18%
Waldenstroem macroglobulinemia
18%
Pyrrole
18%
Pharmacokinetics
18%
Etoposide
15%
Axicabtagene Ciloleucel
13%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
12%
Lomustine
11%
Chlorambucil
11%
Prednisolone
11%
Treatment Group
10%
Cytarabine
10%
Thiotepa
9%
Survival Rate
9%
Clinical Trial
8%
Adverse Event
8%
Hepatotoxicity
7%
Lactate Dehydrogenase
7%
Triazole
7%
Failure Free Survival
6%
Nephrotoxicity
6%
Cyclophosphamide
6%
Immunology and Microbiology
Rituximab
76%
Central Nervous System
54%
Overall Survival
52%
B Cell
40%
Progression Free Survival
36%
Methotrexate
29%
Dexamethasone
24%
Drug Megadose
18%
Human Immunodeficiency Virus
18%
Macroglobulinemia
18%
Prednisolone
18%
Sex Ratio
18%
Aspergillus
18%
Granulocyte Colony-Stimulating Factor
18%
Chimeric Antigen Receptor T-Cell
18%
Mental Health
18%
CD19
18%
Polymerase Chain Reaction
18%
Survival Rate
16%
Arm
14%
Axicabtagene Ciloleucel
13%
Autologous Stem Cell Transplantation
12%
Event Free Survival
9%
Cerebrospinal Fluid
8%
Spinal Cord
6%
Magnetic Resonance Imaging
6%